Compare BCRX & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCRX | WD |
|---|---|---|
| Founded | 1986 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1995 | 2010 |
| Metric | BCRX | WD |
|---|---|---|
| Price | $9.52 | $44.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $20.82 | ★ $78.33 |
| AVG Volume (30 Days) | ★ 5.9M | 386.5K |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 6.25% |
| EPS Growth | ★ 381.40 | N/A |
| EPS | 1.21 | ★ 1.64 |
| Revenue | $25,186,000.00 | ★ $1,234,306,000.00 |
| Revenue This Year | N/A | $20.60 |
| Revenue Next Year | $12.55 | $7.79 |
| P/E Ratio | ★ $7.83 | $26.51 |
| Revenue Growth | N/A | ★ 8.99 |
| 52 Week Low | $6.00 | $42.12 |
| 52 Week High | $11.31 | $90.00 |
| Indicator | BCRX | WD |
|---|---|---|
| Relative Strength Index (RSI) | 64.59 | 36.15 |
| Support Level | $7.85 | $42.12 |
| Resistance Level | $10.32 | $66.25 |
| Average True Range (ATR) | 0.60 | 1.65 |
| MACD | -0.03 | 0.41 |
| Stochastic Oscillator | 65.44 | 30.62 |
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.